Holen Sie sich die Stockscreener-App
0.31
2.21%
-0.007
Vorhandelsmarkt:
.31
Schlusskurs vom Vortag:
$0.317
Offen:
$0.31
24-Stunden-Volumen:
476.70K
Relative Volume:
0.08
Marktkapitalisierung:
$5.29M
Einnahmen:
$743.00K
Nettoeinkommen (Verlust:
$-7.63M
KGV:
-0.1033
EPS:
-3
Netto-Cashflow:
-
1W Leistung:
-9.36%
1M Leistung:
-24.15%
6M Leistung:
-72.07%
1J Leistung:
-80.62%
1-Tages-Spanne:
$0.3027
$0.318
1-Wochen-Bereich:
$0.3027
$0.3484
52-Wochen-Spanne:
$0.28
$2.33
Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile
Firmenname
Can-Fite Biopharma Ltd ADR
Sektor
Branche
Telefon
972 3 924 1114
Adresse
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
Vergleichen Sie CANF mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CANF
Can-Fite Biopharma Ltd ADR
|
0.31 | 5.41M | 743.00K | -7.63M | 0 | -3.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Can-Fite Biopharma Ltd ADR Stock (CANF) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2017-08-11 | Eingeleitet | Maxim Group | Buy |
| 2016-10-19 | Fortgesetzt | ROTH Capital | Buy |
| 2016-08-29 | Fortgesetzt | Rodman & Renshaw | Buy |
| 2015-11-30 | Bestätigt | H.C. Wainwright | Buy |
| 2015-03-31 | Bestätigt | H.C. Wainwright | Buy |
| 2015-03-30 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2014-12-29 | Bestätigt | ROTH Capital | Buy |
| 2014-11-18 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Can-Fite Biopharma Ltd ADR Aktie (CANF) Neueste Nachrichten
Does Can-Fite Biopharma Ltd ADR (CANF) offer a good opportunity for investors? - Setenews
Can Can Fite Biopharma Ltd Sponsored ADR stock survive global slowdown2025 Price Momentum & AI Based Trade Execution Alerts - Newser
Will Can Fite Biopharma Ltd Sponsored ADR stock see insider accumulation2025 Fundamental Recap & Daily Technical Forecast Reports - Newser
Can Can Fite Biopharma Ltd Sponsored ADR stock sustain breakout momentum2025 Investor Takeaways & Expert Approved Momentum Ideas - Newser
Can Can Fite Biopharma Ltd Sponsored ADR stock test all time highsMarket Performance Report & Free Expert Approved Momentum Trade Ideas - Newser
How big funds are accumulating Can Fite Biopharma Ltd Sponsored ADR stockDividend Hike & AI Enhanced Trade Execution Alerts - Newser
Is Can Fite Biopharma Ltd Sponsored ADR stock positioned for secular growth2025 Key Lessons & Growth Focused Entry Reports - Newser
Can Can Fite Biopharma Ltd Sponsored ADR stock deliver double digit returnsJuly 2025 Short Interest & Fast Moving Stock Watchlists - Newser
An analyst sees good growth prospects for Can-Fite Biopharma Ltd ADR (CANF) - Setenews
Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference - Sahm
12 Health Care Stocks Moving In Monday's After-Market Session - Sahm
You might want to take a look at Pasithea Therapeutics Corp (KTTA) now - Setenews
Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil - Sahm
Will Can Fite Biopharma Ltd Sponsored ADR stock beat revenue estimatesQuarterly Performance Summary & Scalable Portfolio Growth Ideas - newser.com
Why Can Fite Biopharma Ltd Sponsored ADR stock is a strong analyst pickJuly 2025 Intraday Action & Capital Efficient Trading Techniques - newser.com
Can Can Fite Biopharma Ltd Sponsored ADR stock expand revenue streams - newser.com
Take off with Santech Holdings Ltd. ADR (STEC): Get ready for trading - Setenews
How does Can-Fite Biopharma Ltd ADR (CANF) change from a tortoise to a hare? - Setenews
Can-Fite BioPharma (NYSE American: CANF) reports 9-year Namodenoson response in HCC - Stock Titan
Finanzdaten der Can-Fite Biopharma Ltd ADR-Aktie (CANF)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):